Unjha Formul.

{
  "main_header": {
    "sid": 782664,
    "name": "Unjha Formul.",
    "stock_name": "Unjha Formul.",
    "full_name": "Unjha Formulations Ltd",
    "name_url": "stocks-analysis/unjha-formul",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "22.95",
    "chg": -0.11,
    "chgp": "-0.48%",
    "dir": -1,
    "prev_price": "23.06",
    "mcapval": "10.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 531762,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE576D01015",
    "curr_date": "Feb 06",
    "curr_time": "",
    "bse_nse_vol": "1.19 k",
    "exc_status": "Active",
    "traded_date": "Feb 06, 2026",
    "traded_date_str": "2026 02 06",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/unjha-formul-782664-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Unjha Formulations Gains 4.32%: Margin Pressures and Flat Growth Shape the Week",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/unjha-formulations-gains-432-margin-pressures-and-flat-growth-shape-the-week-3826346",
        "imagepath": "",
        "date": "2026-02-07 15:06:27",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <div class=\"highlight-box\">\n                    <h3>Key Events This Week</h3>\n                    <p><strong>2 Feb:</strong> Stock opens steady at Rs.22.00 amid Sensex decline</p>\n                    <p><strong>3 Feb:</strong> Stock edges up 0.64% as Sensex rallies 2.63%</p>\n                    <p><strong>4 Feb:</strong> Q3 FY26 results reveal profitability plunge and margin pressures</p>\n                    <p><strong>5 Feb:</strong> Flat quarterly performance confirmed; stock surges 2.53%</p>\n                    <p><strong>6 Feb:</strong> Week closes at Rs.22.95, slightly down 0.48% on the day</p>\n                </div>\n\n                <div class=\"stats-row\">\n                    <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.22.00</div></div>\n..."
      },
      {
        "title": "Unjha Formulations Ltd Reports Flat Quarterly Performance Amid Margin Pressures",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/unjha-formulations-ltd-reports-flat-quarterly-performance-amid-margin-pressures-3821507",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/UnjhaFormulatio_fintrenddot_3821507.png",
        "date": "2026-02-05 08:00:24",
        "description": "Unjha Formulations Ltd, a player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended December 2025, signalling a notable shift from its previously positive growth trajectory. Despite a modest increase in profit after tax (PAT) over the last six months, the company’s overall financial trend score has deteriorated sharply, prompting a downgrade in its Mojo Grade to Strong Sell."
      },
      {
        "title": "Are Unjha Formulations Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-unjha-formulations-ltd-latest-results-good-or-bad-3821002",
        "imagepath": "",
        "date": "2026-02-04 19:18:29",
        "description": "Unjha Formulations Ltd's latest financial results for Q3 FY26 reveal a company facing significant operational challenges despite some positive revenue growth. The company reported net sales of ₹4.41 crores, reflecting a year-on-year increase of 17.29% from ₹3.76 crores in Q3 FY25. However, this growth was overshadowed by a sharp decline in profitability, with net profit falling to ₹0.24 crores, a decrease of 70.73% quarter-on-quarter from ₹0.82 crores in Q2 FY26.\n\nThe operating margin also contracted dramatically from 18.41% to 5.67%, indicating severe pressure on cost management and pricing power. This margin compression raises concerns about the company's operational efficiency, especially as employee costs increased significantly during the quarter. The profit after tax margin also deteriorated, dropping to 5.44% from 19.11% in the previous quarter, highlighting vulnerabilities in earnings quality.\n\nDesp..."
      },
      {
        "title": "Unjha Formulations Q3 FY26: Profitability Plunges Amid Margin Compression",
        "link": "https://www.marketsmojo.com/news/result-analysis/unjha-formulations-q3-fy26-profitability-plunges-amid-margin-compression-3820971",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/UnjhaFormulatio_quaterlyResult_3820971.png",
        "date": "2026-02-04 17:46:54",
        "description": "Unjha Formulations Ltd., a Gujarat-based pharmaceutical company specialising in Ayurvedic and Isabgol (Psyllium) formulations, reported a concerning quarter in Q3 FY26, with net profit plummeting 70.73% quarter-on-quarter to ₹0.24 crores from ₹0.82 crores in Q2 FY26. Despite modest revenue growth of 2.80% QoQ, the company's profitability came under severe pressure from margin compression."
      },
      {
        "title": "Why is Unjha Formulations Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-unjha-formulations-ltd-fallingrising-3808468",
        "imagepath": "",
        "date": "2026-01-29 00:47:57",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Short-Term Gains Outpace Benchmark</strong></p>\n<p>Unjha Formulations has outperformed its sector and the broader market in the immediate term. Over the past week, the stock surged by 5.76%, significantly surpassing the Sensex’s modest 0.53% gain during the same period. This recent rally suggests renewed investor interest and confidence in the stock’s near-term prospects, even as broader market conditions remain mixed.</p>\n<p>Today’s price movement further underscores this trend, with the stock outperforming its sector by 1.13%. The consecutive four-day gain indicates a positive shift in market sentiment, which may be driven by short-term technical factors or speculative buying. However, it is important to note that the stock’s current price remains below its 20-day, 50-day, 100-day, and 200..."
      },
      {
        "title": "When is the next results date for Unjha Formulations Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-unjha-formulations-ltd-3799024",
        "imagepath": "",
        "date": "2026-01-21 23:16:10",
        "description": "Unjha Formulations Ltd is scheduled to declare its results on 04 February 2026...."
      },
      {
        "title": "Unjha Formulations Ltd Upgraded to Hold as Technicals Improve Amid Mixed Financials",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/unjha-formulations-ltd-upgraded-to-hold-as-technicals-improve-amid-mixed-financials-3774325",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/UnjhaFormulatio_mojoScore_3774325.png",
        "date": "2025-12-30 08:18:51",
        "description": "Unjha Formulations Ltd has seen its investment rating upgraded from Sell to Hold as of 29 December 2025, reflecting a nuanced improvement across technical indicators, valuation metrics, and recent financial performance. Despite lingering challenges in long-term fundamentals and market underperformance, the company’s evolving technical trend and attractive valuation have prompted a reassessment of its outlook within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Unjha Formulations Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/unjha-formulations-ltd-is-rated-sell-3768649",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/UnjhaFormulatio_mojoScore_3768649.png",
        "date": "2025-12-24 20:23:06",
        "description": "Unjha Formulations Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 December 2025, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance."
      },
      {
        "title": "Unjha Formulations Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/unjha-formulations-downgraded-to-sell-amid-mixed-financial-and-technical-signals-3740563",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/UnjhaFormulatio_mojoScore_3740563.png",
        "date": "2025-12-02 08:19:35",
        "description": "Unjha Formulations, a player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in market assessment driven by a combination of technical trends, valuation metrics, financial performance, and broader market returns. This article analyses the key factors influencing the recent revision in the company’s evaluation, providing investors with a comprehensive understanding of the current landscape."
      }
    ],
    "total": 133,
    "sid": "782664",
    "stock_news_url": "https://www.marketsmojo.com/news/unjha-formulations-782664"
  },
  "announcements": [
    {
      "caption": ":Publish Un-Audited Financial Results For The Quarter & Nine Month Ended As On 31/12/2025",
      "datetime": "05-Feb-2026",
      "details": "Regulation 33 (3) of SEBI (LODR) Act 2015",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Approval Of Un-Audited Financial Results Of The Company For 9 Month And Quarter Ended On 31St December2025 And Out Come Of Board Meeting Held On 4Th February 2025.",
      "datetime": "04-Feb-2026",
      "details": "Regulation 33 of LODR Act 2015",
      "source": "BSE"
    },
    {
      "caption": "Approval Of Un-Audited Financial Results Of The Company For 9 Month And Quarter Ended On 31St December2025 And Out Come Of Board Meeting Held On 4Th February 2025.",
      "datetime": "04-Feb-2026",
      "details": "Regulation 33 of SEBO LODR Act 2015",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Unjha Formulations Gains 4.32%: Margin Pressures and Flat Growth Shape the Week

2026-02-07 15:06:27

Key Events This Week

2 Feb: Stock opens steady at Rs.22.00 amid Sensex decline

3 Feb: Stock edges up 0.64% as Sensex rallies 2.63%

4 Feb: Q3 FY26 results reveal profitability plunge and margin pressures

5 Feb: Flat quarterly performance confirmed; stock surges 2.53%

6 Feb: Week closes at Rs.22.95, slightly down 0.48% on the day

Week Open

Rs.22.00

...

Read full news article

Unjha Formulations Ltd Reports Flat Quarterly Performance Amid Margin Pressures

2026-02-05 08:00:24

Unjha Formulations Ltd, a player in the Pharmaceuticals & Biotechnology sector, has reported a flat financial performance for the quarter ended December 2025, signalling a notable shift from its previously positive growth trajectory. Despite a modest increase in profit after tax (PAT) over the last six months, the company’s overall financial trend score has deteriorated sharply, prompting a downgrade in its Mojo Grade to Strong Sell.

Read full news article

Are Unjha Formulations Ltd latest results good or bad?

2026-02-04 19:18:29

Unjha Formulations Ltd's latest financial results for Q3 FY26 reveal a company facing significant operational challenges despite some positive revenue growth. The company reported net sales of ₹4.41 crores, reflecting a year-on-year increase of 17.29% from ₹3.76 crores in Q3 FY25. However, this growth was overshadowed by a sharp decline in profitability, with net profit falling to ₹0.24 crores, a decrease of 70.73% quarter-on-quarter from ₹0.82 crores in Q2 FY26. The operating margin also contracted dramatically from 18.41% to 5.67%, indicating severe pressure on cost management and pricing power. This margin compression raises concerns about the company's operational efficiency, especially as employee costs increased significantly during the quarter. The profit after tax margin also deteriorated, dropping to 5.44% from 19.11% in the previous quarter, highlighting vulnerabilities in earnings quality. Desp...

Read full news article

Unjha Formulations Q3 FY26: Profitability Plunges Amid Margin Compression

2026-02-04 17:46:54

Unjha Formulations Ltd., a Gujarat-based pharmaceutical company specialising in Ayurvedic and Isabgol (Psyllium) formulations, reported a concerning quarter in Q3 FY26, with net profit plummeting 70.73% quarter-on-quarter to ₹0.24 crores from ₹0.82 crores in Q2 FY26. Despite modest revenue growth of 2.80% QoQ, the company's profitability came under severe pressure from margin compression.

Read full news article

Why is Unjha Formulations Ltd falling/rising?

2026-01-29 00:47:57

Short-Term Gains Outpace Benchmark

Unjha Formulations has outperformed its sector and the broader market in the immediate term. Over the past week, the stock surged by 5.76%, significantly surpassing the Sensex’s modest 0.53% gain during the same period. This recent rally suggests renewed investor interest and confidence in the stock’s near-term prospects, even as broader market conditions remain mixed.

Today’s price movement further underscores this trend, with the stock outperforming its sector by 1.13%. The consecutive four-day gain indicates a positive shift in market sentiment, which may be driven by short-term technical factors or speculative buying. However, it is important to note that the stock’s current price remains below its 20-day, 50-day, 100-day, and 200...

Read full news article

When is the next results date for Unjha Formulations Ltd?

2026-01-21 23:16:10

Unjha Formulations Ltd is scheduled to declare its results on 04 February 2026....

Read full news article

Unjha Formulations Ltd Upgraded to Hold as Technicals Improve Amid Mixed Financials

2025-12-30 08:18:51

Unjha Formulations Ltd has seen its investment rating upgraded from Sell to Hold as of 29 December 2025, reflecting a nuanced improvement across technical indicators, valuation metrics, and recent financial performance. Despite lingering challenges in long-term fundamentals and market underperformance, the company’s evolving technical trend and attractive valuation have prompted a reassessment of its outlook within the Pharmaceuticals & Biotechnology sector.

Read full news article

Unjha Formulations Ltd is Rated Sell

2025-12-24 20:23:06

Unjha Formulations Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 24 December 2025, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.

Read full news article

Unjha Formulations Sees Shift in Market Assessment Amid Mixed Financial and Technical Signals

2025-12-02 08:19:35

Unjha Formulations, a player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in market assessment driven by a combination of technical trends, valuation metrics, financial performance, and broader market returns. This article analyses the key factors influencing the recent revision in the company’s evaluation, providing investors with a comprehensive understanding of the current landscape.

Read full news article

View All News